Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?
| Autor: | Herr Daniel, Mavrova Russalina, Schmidt Gilda, Moga Simona, Hasenfus Andrea, Juhasz-Böss Ingolf, Rainer M. Bohle, Radosa Julia, Solomayer Erich |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Article Subject Receptor ErbB-2 medicine.medical_treatment lcsh:Medicine Breast Neoplasms General Biochemistry Genetics and Molecular Biology Stable Disease Breast cancer Internal medicine medicine Humans Mammography Neoadjuvant therapy Retrospective Studies Chemotherapy Predictive marker General Immunology and Microbiology biology medicine.diagnostic_test business.industry lcsh:R Retrospective cohort study General Medicine Middle Aged medicine.disease Neoadjuvant Therapy Ki-67 Antigen Ki-67 biology.protein Female business Research Article |
| Zdroj: | BioMed Research International BioMed Research International, Vol 2014 (2014) |
| ISSN: | 2314-6141 2314-6133 |
| Popis: | Background. Currently the choice of breast cancer therapy is based on prognostic factors. The proliferation marker Ki-67 is used increasingly to determine the method of therapy. The current study analyses the predictive value of Ki-67 in foreseeing breast cancer patients’ responses to neoadjuvant chemotherapy.Methods. This study includes patients with invasive breast cancer treated between 2008 and 2013. The clinical response was assessed by correlating Ki-67 to histological examination, mammography, and ultrasonography findings.Results. The average Ki-67 value in our patients collectively (n=77) is 34.9 ± 24.6%. The average Ki-67 value is the highest with 37.4 ± 24.0% in patients with a pCR. The Ki-67 values do not differ significantly among the 3 groups: pCR versus partial pathological response versus stable disease/progress (P=0.896). However, Ki-67 values of patients with luminal, Her2 enriched, and basal-like cancers differed significantly from each other. Furthermore, within the group of luminal tumors Ki-67 values of patients with versus without pCR also differed significantly.Conclusion. Our data shows that the Ki-67 value predicts the response to neoadjuvant chemotherapy as a function of the molecular subtype, reflecting the daily routine concerning Ki-67 and its impressing potential and limitation as a predictive marker for neoadjuvant chemotherapy response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|